𝕏
Latest

Author

Priya Lennox

Regulatory and policy correspondent

Priya Lennox covers FDA and EMA decisions, drug pricing and health policy for PharmaWire, and oversees the FDA decision calendar.

Latest from Priya Lennox

Policy

Navigating Trump’s New Pharmaceutical Tariffs

New tariffs introduced by Donald Trump in April 2026 create significant legal and compliance challenges for pharmaceutical companies. The policy imposes tariffs of up to 100% on patented drugs and related ingredients under Section 232 of…

Regulatory

FDA National Priority Vouchers for Psychedelics

An April 2026 executive order from Donald Trump introduces major changes to how psychedelic drugs could be reviewed and accessed in the U.S. The policy creates two new pathways: a faster U.S. Food and Drug Administration review process…

Policy

Trump secures final drug pricing accord with Regeneron

US President Donald Trump has announced a pricing agreement with Regeneron Pharmaceuticals, marking the final deal in a series of negotiations between the administration and leading drugmakers aimed at lowering the cost of medicines in the…